These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 2673025)

  • 21. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review.
    Olejniczak K; Kasprzak A
    Med Sci Monit; 2008 Oct; 14(10):RA179-89. PubMed ID: 18830208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunologic reconstitution, autoimmunity, and T-cell immune deficiencies.
    Ballow M; McLean RH; Damjanov I; Lowenstein MB
    Cell Immunol; 1979 Jul; 45(2):364-76. PubMed ID: 380821
    [No Abstract]   [Full Text] [Related]  

  • 23. Autoantibody, autoimmune disease, and immunodeficiency.
    Ammann AJ; Wara DW; Pillarisetty RJ; Talal N
    Arthritis Rheum; 1977 Mar; 20(2 Suppl):434-40. PubMed ID: 318125
    [No Abstract]   [Full Text] [Related]  

  • 24. Lymphocyte subsets and surface molecules in man.
    Krensky AM; Lanier LL; Engleman EG
    Clin Immunol Rev; 1985; 4(1):95-138. PubMed ID: 2992859
    [No Abstract]   [Full Text] [Related]  

  • 25. beta-Glycosphingolipids as immune modulators.
    Adar T; Ilan Y
    J Immunotoxicol; 2008 Apr; 5(2):209-20. PubMed ID: 18569392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defective T cell response to presented antigen in autoimmune mice.
    Fischbach M
    J Immunol; 1984 Nov; 133(5):2365-8. PubMed ID: 6332846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of suppressor T cells in lymphopoietic disorders.
    Steinberg AD; Klassen LW
    Clin Haematol; 1977 Jun; 6(2):439-78. PubMed ID: 71963
    [No Abstract]   [Full Text] [Related]  

  • 28. [The expression of IL-2 receptor alpha subunit in T cells].
    Liu CB; Arai K
    Nihon Rinsho; 1997 Mar; 55 Suppl 1():183-8. PubMed ID: 9097585
    [No Abstract]   [Full Text] [Related]  

  • 29. Receptor-mediated endocytosis of IL-2 by PHA stimulated lymphocytes.
    Lee TP; Mookerjee BK
    Transplant Proc; 1989 Feb; 21(1 Pt 1):100-2. PubMed ID: 2784877
    [No Abstract]   [Full Text] [Related]  

  • 30. The suppressor-cell network in cancer (second of two parts).
    Broder S; Waldmann TA
    N Engl J Med; 1978 Dec; 299(24):1335-41. PubMed ID: 362202
    [No Abstract]   [Full Text] [Related]  

  • 31. Human interleukin-2-IgM heavy-chain-fusion proteins are cytotoxic for cells expressing the IL2 receptor.
    Vie H; Gauthier T; Breathnach R; Bonneville M; Godard A; Dietrich J; Karam G; Gesnel MC; Peyrat MA; Jacques Y
    Transplant Proc; 1993 Feb; 25(1 Pt 1):741-2. PubMed ID: 8438463
    [No Abstract]   [Full Text] [Related]  

  • 32. Regulatory T cells: magic bullets for immunotherapy?
    Frey O; Bräuer R
    Arch Immunol Ther Exp (Warsz); 2006; 54(1):33-43. PubMed ID: 16642255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The interleukin 2 receptor and its physiology. Implications for combatting autoimmune diseases and transplant rejections.
    Diamantstein T
    Behring Inst Mitt; 1987 Jun; (81):73-87. PubMed ID: 3115248
    [No Abstract]   [Full Text] [Related]  

  • 34. Immune deficiency of the uremic patient.
    Chatenoud L; Herbelin A; Beaurain G; Descamps-Latscha B
    Adv Nephrol Necker Hosp; 1990; 19():259-74. PubMed ID: 2105582
    [No Abstract]   [Full Text] [Related]  

  • 35. [Analysis of T-lymphocytes and B-lymphocytes].
    Nakagawa T; Yata J
    Nihon Rinsho; 1976; 34 suppl():2653-71. PubMed ID: 792528
    [No Abstract]   [Full Text] [Related]  

  • 36. The IL-2/IL-2 receptor system: a target for rational immune intervention.
    Waldmann TA
    Immunol Today; 1993 Jun; 14(6):264-70. PubMed ID: 8397768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic use of interleukins: experimental results.
    Granstein RD; Tominaga A; Greene MI
    Surv Immunol Res; 1984; 3(2-3):127-34. PubMed ID: 6609400
    [No Abstract]   [Full Text] [Related]  

  • 38. High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth.
    Rao BM; Driver I; Lauffenburger DA; Wittrup KD
    Biochemistry; 2005 Aug; 44(31):10696-701. PubMed ID: 16060678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 1977 Bela Schick Memorial Lecture: disorders of suppressor cells in the pathogenesis of immunodeficiency, autoimmune and allergic diseases: human disease associated with disorders of an immunological breaking system.
    Waldmann TA
    Ann Allergy; 1977 Aug; 39(2):79-86. PubMed ID: 329718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic measures in immunology].
    Russo L
    Minerva Anestesiol; 1978 Oct; 44(10):737-79. PubMed ID: 375127
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.